NCT03715933 2026-03-18
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Phase 1 Recruiting
Clinical Trials
13 trialsNCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT06794645 2025-01-27
Pembrolizumab and Pemetrexed for Progressive Chordoma
Saint John's Cancer Institute
Phase 2 Recruiting
NCT03809637 2024-12-18
A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma
Yonsei University
Phase 2 Completed
NCT03955042 2023-03-07
Pemetrexed for the Treatment of Chordoma
Saint John's Cancer Institute
Phase 1 Completed
NCT04861948 2022-10-04
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT00860015 2020-08-25
Alimta Plus Gemcitabine for Advanced Sarcoma
Columbia University
Phase 2 Completed
NCT00276783 2020-03-05
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
Phase 2 Unknown
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00107419 2012-01-18
S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00523419 2011-06-28
Chemotherapy for Patients With Osteosarcoma
Eli Lilly and Company
Phase 2 Completed
NCT00520936 2011-02-25
A Study of Pemetrexed in Children With Recurrent Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00427466 2009-02-16
Pemetrexed in Patients With Soft Tissue Sarcoma
University Hospital Tuebingen
Phase 2 Completed